Published in Dig Dis Sci on September 08, 2010
Protecting the Kidney in Liver Transplant Recipients: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant (2016) 0.77
Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients. Hepat Med (2011) 0.75
Conversion to combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy for renal dysfunction in liver transplant patients: never too late? Dig Dis Sci (2011) 0.75
Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med (2003) 8.47
A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med (1994) 4.22
Mycophenolate mofetil and its mechanisms of action. Immunopharmacology (2000) 3.41
Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet (2001) 2.39
End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation (2001) 1.79
Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation (2005) 1.75
Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients. Am J Transplant (2006) 1.66
Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl (2004) 1.58
Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl (2008) 1.56
Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation (1998) 1.49
Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant (2008) 1.29
In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther (2007) 1.14
Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles? Cardiovasc Res (2005) 0.98
Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation (2005) 0.96
Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl (2006) 0.96
Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl (2005) 0.93
Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant (2007) 0.89
Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs (2004) 0.88
Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation (2003) 0.88
Mycophenolate mofetil monotherapy in liver transplantation. Lancet (2001) 0.87
Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation (2005) 0.87
Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol (2005) 0.87
Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients--assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther (2007) 0.86
Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation (2005) 0.86
Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation (2003) 0.85
Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int (2002) 0.84
Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transplant Proc (2004) 0.84
Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. Curr Med Res Opin (2006) 0.83
Mechanisms of nephrotoxicity. Transplantation (2000) 0.83
Determinants of mycophenolic acid levels after renal transplantation. Ther Drug Monit (2005) 0.82
Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc (2005) 0.81
Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl (2004) 0.80
Kidney dysfunction in the recipients of liver transplants. Liver Transpl (2005) 0.80
Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. Liver Transpl (2007) 0.80
Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant. Clin Transplant (2009) 0.78
Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation (2000) 0.78
Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant (2001) 0.77
Immunosuppression for long-term maintenance of renal allograft function. Drugs (2004) 0.77
Glomerular filtration rate after liver transplantation with a low-dose cyclosporin protocol. Transpl Int (1994) 0.75
Effects of mycophenolic acid on human renal proximal and distal tubular cells in vitro. Nephrol Dial Transplant (2000) 0.75
Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction. Clin Transplant (2005) 0.75
Resection of colorectal liver metastases. World J Surg (1995) 7.73
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (2001) 5.75
Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg (1990) 4.36
Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg (2004) 3.90
Factors influencing the natural history of colorectal liver metastases. Lancet (1994) 3.61
Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery (1991) 3.35
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg (2001) 2.94
IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol (2000) 2.93
Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas (2004) 2.85
Acute necrotizing pancreatitis: treatment strategy according to the status of infection. Ann Surg (2000) 2.73
Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene (1997) 2.58
Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest (1992) 2.54
Pancreatic fistula after pancreatic head resection. Br J Surg (2000) 2.44
Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg (1992) 2.38
Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol (2006) 2.33
Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res (2001) 2.24
The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest (1998) 2.22
The incidence and severity of post-asphyxial encephalopathy in full-term infants. Early Hum Dev (1985) 2.20
Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res (1993) 2.15
Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res (1993) 2.08
Neuroimmune appendicitis. Lancet (1999) 2.05
Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol (1993) 2.05
[The diagnostic value of the amino acid absorption test in detection of a disorder of exocrine pancreatic function]. Z Gastroenterol (1992) 2.02
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer (1999) 1.99
Carcinoid of the ampulla of Vater. Clinical characteristics and morphologic features. Cancer (1994) 1.97
Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg (2007) 1.92
Effect of preoperative biliary drainage on surgical outcome after pancreatoduodenectomy. Am J Surg (2001) 1.87
VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer (2008) 1.84
Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg (2011) 1.82
Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer (1999) 1.81
ESPEN guidelines on nutrition in acute pancreatitis. European Society of Parenteral and Enteral Nutrition. Clin Nutr (2002) 1.75
Three-dimensional polyethylene wear of a press-fit titanium prosthesis. Factors influencing generation of polyethylene debris. J Arthroplasty (1997) 1.75
Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res (1997) 1.74
Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res (2001) 1.67
Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer (1995) 1.67
The role of infection in acute pancreatitis. Gut (1999) 1.66
Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human. Hum Mol Genet (2006) 1.63
The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene (1999) 1.63
KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res (1996) 1.59
Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun (1998) 1.52
Randomized trial of duodenum-preserving pancreatic head resection versus pylorus-preserving Whipple in chronic pancreatitis. Am J Surg (1995) 1.52
Biology and music. The music of nature. Science (2001) 1.52
A pancreatic cancer-specific expression profile. Oncogene (1996) 1.50
Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg (2008) 1.50
Immune cell infiltration and growth-associated protein 43 expression correlate with pain in chronic pancreatitis. Gastroenterology (1997) 1.49
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer (1997) 1.47
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut (2001) 1.46
Correlation of polypoid lesions in the distal colorectum and proximal colon in asymptomatic screening subjects. Eur J Gastroenterol Hepatol (1996) 1.45
[Resection of colorectal liver metastases. What prognostic factors determine patient selection?]. Chirurg (2001) 1.44
Treatment of bleeding esophageal varices with cyanoacrylate and polidocanol, or polidocanol alone: results of a prospective study in an unselected group of patients with cirrhosis of the liver. Endoscopy (1997) 1.42
Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg (2005) 1.42
Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol (2003) 1.42
Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas (1999) 1.41
Randomized controlled trial of ultrasonic dissection versus standard surgical technique in open left hemicolectomy or total gastrectomy. Br J Surg (2011) 1.41
Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol (2006) 1.41
Developmental toxicity of the HIV-protease inhibitor indinavir in rats. Teratology (2000) 1.40
[Operation technique determines frequency of recurrence of colorectal carcinoma]. Chirurg (1999) 1.40
Importance of the duodenal passage and pouch volume after total gastrectomy and reconstruction with the Ulm pouch: prospective randomized clinical study. World J Surg (1996) 1.40
Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer (2000) 1.39
NOTES for the cardia: antireflux therapy via transluminal access. Endoscopy (2010) 1.38
Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol (1999) 1.38
Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer (2000) 1.37
Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen (2001) 1.37
The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines. FEBS Lett (2001) 1.37
Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology (1999) 1.36
Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res (1993) 1.36
Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. Ann Surg (1999) 1.34
Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol (1999) 1.33
Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis (2004) 1.33
Herpes simplex virus sepsis and acute liver failure. Clin Transplant (2009) 1.32
Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res (1994) 1.32
Human pancreatic tissue concentration of bactericidal antibiotics. Gastroenterology (1992) 1.31
Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol (1998) 1.30
Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg (1999) 1.27
Cytotoxic cells are activated in cellular infiltrates of alcoholic chronic pancreatitis. Gastroenterology (1997) 1.26
Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer (1995) 1.26
Balance of expression of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in chronic pancreatitis. Z Gastroenterol (1994) 1.25
2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology (1995) 1.24
Prognosis of gastric carcinoid tumours. Digestion (1995) 1.23
Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res (1994) 1.23
Risk of invasive carcinoma in colorectal adenomas assessed by size and site. Int J Colorectal Dis (1997) 1.21
Influence of surgery on metachronous distant metastases and survival in rectal cancer. J Clin Oncol (1998) 1.21
Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut (2005) 1.20
Role of phospholipase A2 in human acute pancreatitis. Gastroenterology (1989) 1.20
Randomized clinical trial of the influence of local water-filtered infrared A irradiation on wound healing after abdominal surgery. Br J Surg (2006) 1.19
Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun (1994) 1.18
Technical aspects of left-sided pancreatic resection for cancer. Dig Surg (1999) 1.17
Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res (1997) 1.17
Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys (1990) 1.17
Fast track--different implications in pancreatic surgery. J Gastrointest Surg (2007) 1.16
Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer (2002) 1.16
Invasive carcinoma in colorectal adenomas: multivariate analysis of patient and adenoma characteristics. Endoscopy (1997) 1.14
Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther (2005) 1.14
Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. Int J Cancer (1998) 1.13
Increased expression of keratinocyte growth factor in human pancreatic cancer. Biochem Biophys Res Commun (1995) 1.13
Resection of colorectal liver metastases. Langenbecks Arch Surg (1999) 1.13